

## Preface

TAKING A LOOK BACK, I GLANCED THROUGH the index of the biochemistry textbook from my medical school days to search for cell membranes. There was nothing. I found 20 pages on the lipid constituents of tissues and chapters on lipid metabolism and nutrition, but nothing about the structures that those lipids form or their functional importance. The book was published in 1957. From a current standpoint this is quite shocking and reflects how curricula are continually changing.

By 1925, Gorter and Grendel had already performed their classic experiment revealing that the red blood cell membrane is a lipid bilayer. They used acetone to extract the lipids, determined the surface area of the extracted lipid in a Langmuir trough, and compared this value with the surface area of erythrocytes calculated from dried smears. We now know their studies had two errors. Acetone does not extract all the lipids, but this error was offset by their error in measuring the red cell surface area. Nevertheless, Gorter and Grendel came to the conclusion that the ratio of surface area occupied by lipid to the area of the cell is around 2, a number consistent with the idea that the cell is enveloped by a bimolecular leaflet.

From then on, lipids dominated membrane research. In the Davson–Danielli unit membrane model, proteins were plastered on both sides of the bilayer but no protein was thought to penetrate through the two lipid leaflets. The permeability of cell membranes to ions was postulated to be governed by electrostatic interactions and membrane potential. Because this model could not account for various forms of accelerated ion transport observed across membranes, lipid pores were postulated to extend through the bilayer. This all sounds amazing, but it illustrates how radically our understanding of biology has changed in the past 100 years.

The next phase in membrane research came in the 1960s, when studies of mitochondria and chloroplasts started to challenge the unit membrane concept. Detergent solubilization revealed the existence of lipoprotein subunits in these membranes. In addition, electron microscopy seemed to support a new model of membranes in which they were built from lipoprotein subunits. Thus, membrane proteins had moved center stage and started to attract more and more attention.

It was not until the early 1970s, however, that experiments showed that one and the same protein could be labeled from both sides of the red blood cell plasma membrane; thus the concept of transmembrane proteins was born. The composition of the two lipid leaflets was also found to be asymmetric, with choline-containing lipids in the outer leaflet and phosphatidyl ethanolamine, phosphatidyl serine, and phosphatidyl inositol on the inside. Freeze-fracture studies demonstrated that the cell membranes can be split down the middle, and the fracture planes revealed intramembrane particles thought to represent individual transmembrane proteins.

Also groundbreaking were studies demonstrating that proteins and glycolipids can move laterally in the plane of the membrane, revealing the fluid nature of the lipid bilayer. At that time, my colleagues and I were studying the budding of an enveloped virus, Semliki Forest virus, through the host cell plasma membrane. This budding process was enigmatic because during the assembly of the viral envelope into a specific domain in the plasma membrane, host proteins were excluded but viral envelope proteins were specifically included. Because the dogma in virology was that envelope proteins cannot penetrate the bilayer, no plausible model for the formation of an envelope virus could be formulated. Henrik Garoff and I solved the problem by demonstrating that envelope proteins are transmembrane proteins that connect to the underlying nucleocapsid, which functions as a template for the budding process.

## Preface

This research culminated in the Singer–Nicolson model for cell membranes. In this model, transmembrane proteins were embedded in the bilayer, with peripheral proteins binding to the membrane on both sides. The lipid bilayer became the sea in which protein “icebergs” were free to float around. This is the model that dominated membrane research in the years to come. Meanwhile, recombinant DNA technology caused a revolution in membrane protein research. Quickly, membrane proteins went from being extremely difficult to purify, and therefore to work with, to being characterized in ever-increasing numbers and having their atomic structures determined. Meanwhile, from studies on lipid metabolism, research on membrane biosynthesis moved to the forefront, specifically focusing on assembly of proteins into membranes. The roles of transport vesicle formation and fusion in membrane trafficking became hot areas of research, again with a focus on protein cargo and on the protein machineries involved.

This focus on proteins led to a near-total neglect of the role of lipids in the function of biological membranes. These were relegated backstage and viewed as a boring, inert solvent for hydrophobic proteins. The early insights that specific lipids can regulate membrane protein function were forgotten. In the vast field of signal transduction, roles for lipids as potential allosteric regulators of signaling processes were no longer proposed—indeed, even today, lipids rarely appear in reviews on signal transduction.

The introduction of the “lipid raft” concept that postulated the existence of dynamic membrane subcompartments was a turning point and stirred up the field. From being a passive solvent, the lipid bilayer took on an active role in membrane function. The concept caused controversy, naturally so in an area of research plagued by a lack of technologies to study dynamic processes in two-dimensional fluids. Indeed, the skepticism was evident in the titles of some reviews: “Lipid rafts: Elusive or illusive”<sup>1</sup> or “Lipid rafts: Now you see them, now you don’t.”<sup>2</sup> The accelerating development of novel and sophisticated spectroscopic and imaging technology, however, has allowed cell membrane research to pick up speed. Moreover, the deadlock in generation of analytical tools to study lipid diversity has been broken. Now, cellular lipidomes can be analyzed by sensitive high-resolution mass spectrometry. The question of why our cells make so many different species is beginning to be answered.

It is this excitement that this book tries to catch. Membrane researchers are now starting to include lipids in their repertoire. The protein-only focus will soon be gone. Cell membranes are two-dimensional fluids, composed of a lipid bilayer crowded with proteins; thus, we have to study both the lipids and the proteins together to come to grips with this fascinating fluid.

I wish to thank Richard Sever for persuading me to edit this book, and Barbara Acosta for her untiring support to make it a reality. I also thank all of the authors who agreed to contribute chapters and Kostas Margitidis for drawing the cover.

KAI SIMONS

---

<sup>1</sup>Munro S. 2003. Lipid rafts: Elusive or illusive? *Cell* **115**: 377–388.

<sup>2</sup>Shaw AS. 2006. Lipid rafts: Now you see them, now you don’t. *Nat Immunol* **7**: 1139–1142.

# Index

## A

- ABC transporters, lipid translocation, 141–143AC. *See*  
Lysosomal acid ceramidase
- Actin, phosphoinositides in assembly and organization  
branched actin networks, 210–212  
contractile actomyosin networks, 212–213  
cytoskeletal control of tissue architecture, 214  
overview, 210
- Adherens junction (AJ)  
mechanosensors, 213–214  
phosphoinositide control of stability, 213–214
- Adipocyte, lipid droplets, 273–274
- Adipocyte differentiation-related protein (ADRP), 272,  
274, 276–278
- ADRP. *See* Adipocyte differentiation-related protein
- AFM. *See* Atomic force microscopy
- AJ. *See* Adherens junction
- Alzheimer disease, 233–234
- Amber, 93
- Aminophospholipid flippases, lipid translocation, 141
- Amyloid- $\beta$ , 233–234
- Annular lipid shell  
definition, 222  
examples, 231  
protein–lipid interactions, 224, 228–231
- Area deformation, energy differential equation, 40–41
- ARF1-COPI pathway, 276–277
- Arf-related protein-1, 276–277
- Arylsulphatase A (ASA), 296
- ASA. *See* Arylsulphatase A
- Asymmetry. *See* Transbilayer lipid asymmetry
- ATGL, 275
- Atomic force microscopy (AFM), protein–lipid  
interactions, 225
- Atomistic simulation. *See* Molecular dynamics

## B

- Baz, 213
- Bebivolol, 96
- $\beta$ -Blockers, lipid simulations in design, 96
- Bilayer  
complexity, architecture, and function, 3–4  
models. *See* Membrane models  
proteins, 2–3
- Biosynthetic trafficking, membrane lipids  
glycerophospholipids

- overview, 241–242  
phosphatidylcholine, 241–242  
phosphatidylethanolamine, 241–243  
phosphatidylserine, 242–243  
mechanisms of transport, 240  
overview, 239–241, 249  
prospects for study, 251  
sphingolipids  
glycosphingolipids, 246  
overview, 243–245  
recycling, 246–247  
sphingomyelin, 244–246  
sterols, 247–248, 250–251
- Bis-(monacylglycerol)-phosphate (BMP), 290–291, 294
- BMP. *See* Bis-(monacylglycerol)-phosphate
- Bulk lipid, 222, 224

## C

- CADs. *See* Cationic amphiphilic drugs
- Cationic amphiphilic drugs (CADs), 294
- Caveolae  
lipid droplet interactions, 277  
protein–lipid interactions, 231–232
- CD4, glycosphingolipid modulation of  
function, 158–160
- Cdc42, 209–211
- Ceramide transport protein (CERT), 244,  
246–247, 250, 289
- CERT. *See* Ceramide transport protein
- CESD. *See* Cholesteryl ester storage disease
- Charm, 93
- CHMP2A, 320
- CHMP3, 320
- CHMP4, 319–320
- Cholera toxin (CTx), glycosphingolipid receptor,  
154–155, 256
- Cholesterol. *See also* Sterols  
biosynthetic trafficking, 247–248, 250–251  
coexisting phases in bilayers, 55–58  
gradients and protein Golgi transport, 4  
liquid-ordered phase, 39–40  
post-Golgi protein transport studies  
MDCK cells, 5–6  
yeast, 5  
synthesis regulation. *See* Sterol regulatory  
element-binding protein

## Index

- Cholesteryl ester storage disease (CESD), 299  
Cide proteins, 274  
Coarse-grained models. *See* Molecular dynamics  
CTx. *See* Cholera toxin  
Curvature  
    composition coupling, 72  
    energy requirement equation, 78  
    lipid sorting studies  
        lipid–lipid interactions, 82–86  
        overview, 77–82  
        physico-chemical mechanisms, 80  
        prospects for study, 87–88  
        protein binding enhancement, 86–87  
        two-component membrane energy, 79  
    membrane models, 35  
    pathogen induction, 260–261, 313–316  
    spontaneous curvature, 67–69
- D**  
7-Dehydrocholesterol reductase (DHCR7), 197  
Dengue virus  
    membranes in replication, 312  
    morphogenesis and release, 313  
DHCR7. *See* 7-Dehydrocholesterol reductase  
Differential scanning calorimetry (DSC), protein–lipid interactions, 226  
DSC. *See* Differential scanning calorimetry
- E**  
EGF. *See* Epidermal growth factor  
Electron crystallization, protein–lipid interactions, 225  
Electron paramagnetic resonance (EPR), protein–lipid interactions, 225–226  
Electron spin resonance (ESR), protein–lipid interactions, 225–226  
Endocytosis, lipid-mediated  
    glycosphingolipid receptors  
        curvature induction, 260–261, 313–316  
    endosomal sorting, 262–264  
    initial binding, 257–258  
    lipid domain association, 258–260  
    prospects for study, 264–265  
    scission of endocytic vesicles, 261–262  
    toxin receptors  
        cholera toxin, 154–155  
        overview, 256–257  
        verotoxin, 155–156  
    virus receptors  
        intracellular trafficking, 264  
        overview, 256–257  
        SV40, 259  
    overview, 255
- Endosomal sorting complex required for transport (ESCRT), 315, 319–321  
Epidermal growth factor (EGF), glycosphingolipid modulation of receptor function, 157  
EPR. *See* Electron paramagnetic resonance  
*erg* mutants, 195  
ESCRT. *See* Endosomal sorting complex required for transport  
ESR. *See* Electron spin resonance
- F**  
Fabry disease, 293, 295–296  
Farber disease, 297  
FCCS. *See* Fluorescence  
FCS. *See* Fluorescence  
Filipin, 193  
FIT1, 274  
FIT2, 274  
FLIM-FRET. *See* Fluorescence  
Fluid-mosaic model, 34, 221  
Fluorescence  
    confocal microscopy, 108–109  
    fluorescence correlation spectroscopy  
        challenges  
            background, 119  
            blinking, 119  
            detector dead time and saturation, 120–121  
            photobleaching, 120  
            specific artifacts, 121–122  
        fitting models, 119  
        fluorescence cross-correlation spectroscopy, 116  
        lateral diffusion comparison with fluorescence recovery after photobleaching, 122–123  
        lipid dynamics applications, 122  
        principles, 114–116  
        scanning spectroscopy, 116–118  
        total internal fluorescence illumination, 118  
        two-focus spectroscopy, 118  
        two-photon spectroscopy, 118  
    fluorescence recovery after photobleaching  
        lateral diffusion comparison with fluorescence correlation spectroscopy, 122–123  
        lipid dynamics applications, 113–114  
        photobleaching artifacts, 113  
        principles, 112  
        region of interest size, 113  
        total internal fluorescence illumination, 112–113  
    Förster resonance energy transfer  
        applications, 126  
        difficulties, 125–126  
        FLIM-FRET, 124–125  
        lipid droplet studies, 276  
        principles, 123–125  
    generalized polarization, 107

- historical perspective, 106
  - overview of techniques for lipid dynamics, 105–106
  - principles, 106
  - probes, 107–108
  - protein–lipid interactions, 227
  - single-particle tracking
    - applications, 128–129
    - difficulties, 128
    - fitting models, 127
    - principles, 126–128
  - total internal fluorescence microscopy
    - lipid dynamics applications, 110
    - polarization studies, 110
    - principles, 109–110
  - two-photon microscopy
    - lipid dynamics applications, 111–112
    - principles, 110–111
  - Förster resonance energy transfer. *See* Fluorescence
  - Fourier transform–tandem mass spectroscopy,
    - polyunsaturated lipids, 26–27
  - FRAP. *See* Fluorescence
  - FRET. *See* Fluorescence
- G**
- Gag, 316–318
  - Galactosylsphingosine (GalSo), toxicity, 293
  - GalSo. *See* Galactosylsphingosine
  - Gaucher disease, 293, 295
  - GCS. *See* Glucosyl ceramide synthase
  - Generalized polarization (GP), 107
  - GFP. *See* Green fluorescent protein
  - Giant unilamellar vesicle (GUV)
    - mechanics, 41
    - models, 37–38
  - GlcSo. *See* Glucosylsphingosine
  - GLTP. *See* Glycolipid transfer protein
  - Glucosyl ceramide synthase (GCS)
    - ceramide level regulation, 152
    - inhibitors, 151
    - knockout mice, 152–153
    - subcellular localization, 150–151
  - Glucosylsphingosine (GlcSo), toxicity, 293
  - Glycolipid transfer protein (GLTP), 246
  - Glycophosphatidylinositol (GPI) anchor
    - ceramide in proteins, 198
    - lipid raft–protein interactions, 13
    - plasma membrane dynamic organization, 8–9
  - Glycosphingolipids (GSLs). *See also* Endocytosis,
    - lipid-mediated
      - axonal growth regulation, 157
      - biosynthetic trafficking, 246
      - conformational change, 160–161
      - glucosyl ceramide synthase
        - ceramide level regulation, 152
        - inhibitors, 151
      - knockout mice, 152–153
      - subcellular localization, 150–151
    - lactosyl ceramide
      - cytokine induction, 156
      - Lyn kinase activation, 156
    - lateral organization in membranes, 161–163
    - prospects for study, 164
    - protein trafficking role, 151–152
    - receptor function modulation
      - CD4 and human immunodeficiency virus, 158–160
      - epidermal growth factor, 157
      - insulin, 157–158
      - nerve growth factor, 157
    - stage-specific embryonic antigens, 152–153
    - storage diseases. *See* Lysosomal lipid storage diseases
    - structures, 149–150
    - synthesis, 149–150, 288–289
    - toxin receptors
      - cholera toxin, 154–155
      - curvature induction, 260–261
      - endosomal sorting, 262–264
      - initial binding, 257–258
      - lipid domain association, 258–260
      - overview, 256–257
      - prospects for study, 264–265
      - scission of endocytic vesicles, 261–262
      - verotoxin, 155–156
    - virus receptors
      - intracellular trafficking, 264
      - overview, 256–257
      - SV40, 259
  - GP. *See* Generalized polarization
  - Green fluorescent protein (GFP), 107
  - GROMACS, 93
  - GROMOS, 93
  - GSLs. *See* Glycosphingolipids
  - GUV. *See* Giant unilamellar vesicle
- H**
- HBV. *See* Hepatitis B virus
  - HCV. *See* Hepatitis C virus
  - HDL. *See* High-density lipoprotein
  - Helfrich expression, 40–41
  - Hepatitis B virus (HBV), 316
  - Hepatitis C virus (HCV)
    - entry, 309, 311–312
    - lipid composition, 319
    - lipid droplets in infection, 279
    - membranes in replication, 312–313
    - morphogenesis and release, 315
  - High-density lipoprotein (HDL), molecular dynamics studies, 97–98
  - HIV. *See* Human immunodeficiency virus

## Index

- HMG CoA reductase. *See* Hydroxymethylglutaryl CoA reductase
- Human immunodeficiency virus (HIV)  
entry, 309  
glycosphingolipid modulation of receptor function, 158–160  
lipid composition, 317, 319  
morphogenesis and release, 313, 316–317
- Hydrophobic mismatch, 222
- Hydroxymethylglutaryl (HMG) CoA reductase  
cholesterol synthesis, 247  
regulation of levels, 181–183
- I**
- Influenza virus, 315–316, 321
- Infrared (IR) spectroscopy, protein–lipid interactions, 225
- Inositylphosphoryl ceramide, 191
- Insig  
insulin regulation of expression, 184  
sterol regulatory element-binding protein proteolysis regulation, 177–179
- Insulin  
glycosphingolipid modulation of receptor function, 157–158  
Insig expression regulation, 184
- IR spectroscopy. *See* Infrared spectroscopy
- K**
- Krabbe disease, 296
- L**
- Lactosyl ceramide  
cytokine induction, 156  
Lyn kinase activation, 156
- LAL. *See* Lysosomal acid lipase
- Large unilamellar vesicle (LUV), models, 37
- Lateral pressure field  
definition, 222  
membrane models, 38–39
- LC3-I, 275
- LD. *See* Lipid droplet
- LDL. *See* Low-density lipoprotein
- Lipid bilayer. *See* Bilayer
- Lipid droplet (LD)  
adipocytes, 273–274  
biogenesis, 271–273  
caveolae interactions, 277  
functions  
lipid ester storage, 274–276  
lipid synthesis and metabolism, 275–276  
nonconventional functions, 276  
stored lipid utilization, 275  
interaction with other organelles, 276–277  
motility, 277–278  
overview, 269–270  
pathology  
infection, 279  
lipid storage disease, 278  
motor neuron disease, 278–279  
prospects for study, 279–280  
proteome, 273  
structure, 270–271
- Lipidomics  
mass spectrometry  
individual lipid mass analysis  
polyunsaturated species, 26–27  
structurally related isobaric species, 27–29  
lipid class mass analysis, 21–23  
principles, 19–21  
prospects, 29  
top-down lipidomics screens, 23–25  
overview, 19
- Lipid–protein interactions. *See* Protein–lipid interactions
- Lipid raft  
clustering, 7, 11  
definition, 222  
domain-induced budding, 7  
lipid–protein interactions, 12–13  
membrane models, 40  
nanoscale rafts  
functionalization, 10–11  
plasma membrane dynamic organization, 8–9  
post-Golgi protein transport studies, 6  
signaling, 196–197  
tuning, 11  
virus entry, 309–310
- Lipid sorting. *See* Curvature; Lysosomal lipid storage diseases; Transbilayer lipid asymmetry
- Lipid storage diseases. *See* Lysosomal lipid storage diseases
- Liposome  
discovery, 34  
drug delivery, 44  
models, 36–38
- Liquid-disordered phase, 222
- Liquid-ordered phase, 39–40, 49, 222
- Low-density lipoprotein (LDL), molecular dynamics studies, 97
- LSDs. *See* Lysosomal lipid storage diseases
- LUV. *See* Large unilamellar vesicle
- Lyn kinase, activation via lactosyl ceramide, 156
- Lysosomal acid ceramidase (AC), 297
- Lysosomal acid lipase (LAL), 299
- Lysosomal lipid storage diseases (LSDs)  
cholesteryl ester storage disease, 299  
Fabry disease, 293, 295–296  
Farber disease, 297

- Gaucher disease, 293, 295
  - glycosphingolipids, 153–154, 290–292
  - GM1 gangliosidosis, 294
  - GM2 gangliosidosis
    - AB-variant, 295
    - overview, 294–295
    - Sandhoff disease, 295
    - Tay–Sachs disease, 295
  - Krabbe disease, 296
  - lipid droplets, 278
  - lipid sorting and intraendolysosomal vesicle formation, 290–292
  - lipid-binding proteins, 292–293, 297–298
  - lysosomal perimeter membrane labilization, 294
  - lysosome functions, 280
  - lysosphingolipids as cationic amphiphiles, 293
  - metachromatic leukodystrophy, 296
  - Neimann–Pick disease, 296
  - organ and cell specificity of sphingolipid storage, 292–293
  - overview, 287–288
  - prosaposin deficiency, 297–298
  - sphingolipid accumulation outside endolysosomal system, 293
  - sphingolipidoses, 290–292
  - threshold theory, 293
  - treatment, 299–300
  - Wolman disease, 299
- M**
- MAGI-2. *See* Membrane-associated guanylate-kinase-2
  - Mannose inositol phosphate ceramide (MIPC), 198
  - MAPK. *See* Mitogen-activated protein kinase
  - MARTINI model, 94
  - Mass spectrometry (MS). *See also* Lipidomics
    - sphingolipids, 194
    - sterols, 194
  - MD simulations. *See* Molecular dynamics simulations
  - MDR1, 151
  - Membrane-associated guanylate-kinase-2 (MAGI-2), 213–214
  - Membrane models
    - bilayer proteins, 2–3
    - cholesterol and liquid-ordered phase, 39–40
    - closed bilayers, 36–38
    - historical perspective, 33–34
    - lateral pressure profile, 38–39
    - lipid–protein interactions in reconstituted membranes, 41–43
    - mechanics, 40–41
    - monolayers, 35–36
    - need for new models, 43–44
    - phases, domains, and rafts, 40
    - polymorphisms, 34–35
    - practical applications, 44
    - protein omission in simple models, 52
    - protein–lipid interactions, 221, 223
    - simulations. *See* Molecular dynamics simulations
    - spatial organization in membranes, 50–51
    - supported bilayers and multilayers, 36
  - Metachromatic leukodystrophy (MLD), 296
  - MFQL. *See* Molecular fragmentation query language
  - Microdomain, definition, 222
  - MIPC. *See* Mannose inositol phosphate ceramide
  - Mitogen-activated protein kinase (MAPK), lipids in signaling, 196–197
  - MLD. *See* Metachromatic leukodystrophy
  - Molecular dynamics (MD) simulations
    - coarse-grained models, 92–93
    - complex concerted dynamics in membranes, 99–100
    - drug design, 95–97
    - historical perspective, 91–92
    - lipid–protein interactions, 94–95, 226
    - lipoprotein studies, 97–98
    - prospects, 100–101
    - techniques, 92–94
  - Molecular fragmentation query language (MFQL), 23–24
  - Molecular lipid species, definition, 222
  - Monolayer, models, 35–36
  - MS. *See* Mass spectrometry
  - MsbA, lipid translocation, 143
  - MscL, 228
  - Multivesicular body (MVB), 315
  - MVB. *See* Multivesicular body
- N**
- NAMD, 93
  - Neimann–Pick disease
    - type A, 296
    - type B, 296
    - type C, 298–299
  - Nerve growth factor (NGF), glycosphingolipid modulation of receptor function, 157
  - Neutral lipid storage disease (NLS), 278
  - NGF. *See* Nerve growth factor
  - NLS. *See* Neutral lipid storage disease
  - NM-II. *See* Nonmuscle myosin II
  - NMR. *See* Nuclear magnetic resonance
  - Nonannular lipid
    - definition, 223
    - examples, 230
    - protein–lipid interactions, 231–232
  - Nonmuscle myosin II (NM-II), 212–214
  - NPC1, 142, 294, 298–299
  - NPC2, 292, 298
  - Nuclear magnetic resonance (NMR), protein–lipid interactions, 223, 225

## Index

### O

OPLS, 93  
Orbitrap mass analyzer, 20  
ORP, 250–251

### P

P4 ATPase, lipid translocation, 141–142  
PAR-3, 208–209, 213  
PAR-6, 211, 214  
PAT proteins, 273–274, 277  
PC. *See* Phosphatidylcholine  
PE. *See* Phosphatidylethanolamine  
Perilipin A, 273–274  
Phase separation  
  lipid sorting enhancement, 84  
  lipid types in membranes, 51–52  
  liquid-disordered phase, 49  
  liquid-ordered phase, 39–40, 49  
  overview in plasma membranes, 10, 12  
  phase diagrams  
    cholesterol in bilayers and coexisting phases, 55–58  
    four-component bilayer mixtures, 58  
    lipid clustering from nonideal mixing in single-phase regions, 52–54  
    structured one-phase mixtures, 54–55  
  prospects for study, 59  
  protein omission in simple models, 52  
  spatial organization in membranes  
    modeling, 50–51  
    scales, 49–50  
Phosphatidylcholine (PC), biosynthetic trafficking, 241–242  
Phosphatidylethanolamine (PE), biosynthetic trafficking, 241–243  
Phosphatidylinositol-4-kinase III $\beta$ , 313  
Phosphatidylserine (PS), biosynthetic trafficking, 242–243  
Phosphoinositides (PIs)  
  actin assembly and organization role  
    branched actin networks, 210–212  
    contractile actomyosin networks, 212–213  
    cytoskeletal control of tissue architecture, 214  
    overview, 210  
  apical domain biogenesis role, 207–210  
  junctional stability control, 213  
  kinases and phosphatases, 204–205  
  membrane identity control, 206–207  
  prospects for study, 214–215  
  Ras effectors, 205–206  
  signaling fine tuning, 205  
  subcellular distribution, 204  
    types, 203–204  
PIs. *See* Phosphoinositides  
Plasma membrane  
  dynamic organization, 8–9  
  models. *See* Membrane models  
  phase separation. *See* Phase separation  
  topological plasticity, 73–74  
PMCA, 232  
Polymorphism, lipids  
  molecular organization  
    asymmetry and curvature, 68–69  
    closed membranes and shape diagrams, 69  
    molecular shape and membrane stored stress, 67  
    non-bilayer structures, 67–68  
    self-assembly driving forces, 65–67  
  overview, 2, 34–35, 63–65  
  shape changes  
    domain-driven shape, 73  
    forcing shape, 70–71  
    tuning  
      asymmetry, 71–72  
      curvature–composition coupling, 72  
      nonlocal elasticity, 73  
      protein insertion, 72–73  
  topological plasticity of membranes, 73–74  
Polarity, phosphoinositide signaling, 206–207  
Prosaposin, deficiency, 297–298  
Protein–lipid interactions  
  analysis  
    atomic force microscopy, 225  
    differential scanning calorimetry, 226  
    electron crystallization, 225  
    electron paramagnetic resonance, 225–226  
    electron spin resonance, 225–226  
    fluorescence spectroscopy, 227  
    infrared spectroscopy, 225  
    molecular dynamics simulations, 94–95, 226  
    nuclear magnetic resonance, 223, 225  
    X-ray crystallography, 225  
  annular protein–lipid interactions, 224, 228–231  
  bilayer proteins, 2–3  
  chaperone activity of lipids, 232–234  
  glycosphingolipids in trafficking, 151–152  
  lipid raft interactions, 13  
  lipid sorting enhancement, 86–87  
  membrane models, 221, 223  
  nonannular protein–lipid interactions, 224, 231–232  
  prospects for study, 234–235  
  protein insertion in lipid polymorphism fine tuning, 72–73  
  reconstituted membrane studies, 41–43  
PS. *See* Phosphatidylserine  
PTEN, 207–209, 212–215

## Q

QENS. *See* Quasi-elastic neutron scattering  
Quasi-elastic neutron scattering (QENS), 99–100

## R

RAFIs. *See* Rigid amphipathic fusion inhibitors  
Ras, phosphoinositide effectors, 205–206  
Regulated intramembrane proteolysis. *See* Sterol  
regulatory element-binding protein  
RFT1, lipid translocation, 142  
Rhodopsin, 232  
Rigid amphipathic fusion inhibitors (RAFIs), 311  
ROCK, 212–213

## S

Sandhoff disease, 295  
Sap-A, 297  
Sap-B, 297  
Sap-C, 297  
Sap-D, 297–298  
SAR1-COPII pathway, 277  
SC. *See* Spontaneous curvature  
Scap  
knockout mouse, 182  
sterol regulatory element-binding protein  
proteolysis regulation, 177–178  
Scramblases, lipid translocation, 142–143  
Self-assembly, driving forces for  
lipids, 65–67  
Semliki Forest virus (SFV)  
lipid composition, 319  
membranes in replication, 312  
Serine palmitoyl transferase (SPT), 192  
SFV. *See* Semliki Forest virus  
Shape. *See* Polymorphism, lipids  
Simulations. *See* Molecular dynamics simulations  
Single-particle tracking (SPT)  
applications, 128–129  
difficulties, 128  
fitting models, 127  
fluorescence techniques, 126–128  
Small unilamellar vesicle (SUV), models, 37  
Spartin/SPG20, 278  
Sphingolipids  
activator proteins, 246  
biosynthesis, 191, 193–194  
biosynthetic trafficking  
glycosphingolipids, 246  
overview, 243–245  
recycling, 246–247  
sphingomyelin, 244–246  
functional genetics studies, 194–198  
long-chain bases, 195, 197

post-Golgi protein transport studies  
MDCK cells, 5–6  
yeast, 5  
separation and detection, 194  
signal transduction, 196–198  
sphingolipidoses. *See* Lysosomal lipid storage  
diseases  
structures and distribution among species, 190–192  
subcellular distribution, 193–194  
Spontaneous curvature (SC), 67–69  
SPT. *See* Serine palmitoyl transferase; Single-particle  
tracking  
SREBP. *See* Sterol regulatory element-binding protein  
SSEAs. *See* Stage-specific embryonic antigens  
Stage-specific embryonic antigens (SSEAs), 152–153  
StAR. *See* Steroidogenic acute regulatory protein  
StARDs, 241  
START domain  
CERT, 244  
steroidogenic acute regulatory protein, 250  
Steroidogenic acute regulatory protein (StAR), 250  
Sterol regulatory element-binding protein (SREBP)  
fatty acid regulation, 179  
isoforms, 175, 191  
liver pathway regulation  
knockout mouse studies, 182–183  
nuclear protein overexpression studies, 180–181  
overview, 179–180  
transcriptional regulation, 183–184  
prospects for study, 184  
regulated intramembrane proteolysis  
activation and regulation, 176–177  
Insig regulation, 177–179  
Scap regulation, 177–178  
structure, 175–176  
transport, 175–176  
Sterols. *See also* Cholesterol  
biosynthetic trafficking, 247–248, 250–251  
functional genetics studies, 194–198  
separation and detection, 194  
structures and distribution among species, 190–192  
subcellular distribution, 192–194  
synthesis regulation. *See* Sterol regulatory  
element-binding protein  
Supported bilayer, models, 36  
SUV. *See* Small unilamellar vesicle  
SV40, 259

## T

TAG. *See* Triacylglycerol  
Target of rapamycin (TOR), 195–196  
Tat2, sorting to vacuole, 195–196  
Tay-Sachs disease, B-variant, 295  
TGH. *See* Triglyceride hydrolase

## Index

- Theonellamide (TNM), 193, 197  
TIAM, 211  
Tight junction (TJ), phosphoinositide control of stability, 213  
TIRF microscopy. *See* Total internal fluorescence microscopy  
TJ. *See* Tight junction  
TMD. *See* Transmembrane domain  
TNM. *See* Theonellamide  
TOR. *See* Target of rapamycin  
Total internal fluorescence (TIRF) microscopy  
  lipid dynamics applications, 110  
  polarization studies, 110  
  principles, 109–110  
TRAAK, 228  
Transbilayer lipid asymmetry  
  erythrocytes, 138  
  lipid translocation studies  
    bacterial and mitochondrial membranes, 143  
    erythrocytes, 140  
    model membranes, 140  
    nucleated cells  
      aminophospholipid flippases, 141  
      ABC transporters, 141–142  
      scramblases, 142  
      miscellaneous translocators, 142–143  
    viral membranes, 141  
  model membranes, 138  
  nucleated cells, 139–140  
  overview, 137–138  
  polymorphism  
    curvature, 68–69  
    tuning, 71–72  
  prospects for study, 143  
  viral membranes, 138–139  
Transmembrane domain (TMD)  
  length and Golgi transport, 4  
  lipid chaperone interactions, 233–234  
TREK-1, 228  
Triacylglycerol (TAG), tandem mass spectroscopy, 27–28  
Triglyceride hydrolase (TGH), 275  
Troyer syndrome, 278  
Tuba, 210  
Two-photon microscopy  
  lipid dynamics applications, 111–112  
  principles, 110–111
- V**
- Verotoxin (VT), glycosphingolipid receptor, 155–156  
Very low-density lipoprotein (VLDL), 275, 315  
Vesicles, models, 36–38  
Vesicular stomatitis virus (VSV), 308, 319  
Virus replication. *See also* Endocytosis, lipid-mediated;  
  *specific viruses*  
  curvature induction, 260–261, 313–316  
  entry  
    inhibitors of fusion, 310–312  
    membrane fusion, 310–312  
    pathways, 308–310  
  lipid composition of viruses, 317, 319  
  morphogenesis and release, 313–321  
  overview, 307–308  
  prospects for study, 321  
  scission of membranes, 261–262, 319–321  
  transbilayer lipid asymmetry, 141  
  viral component association with membranes,  
    316–317  
VLDL. *See* Very low-density lipoprotein  
Vps4, 319–321  
VSV. *See* Vesicular stomatitis virus  
VT. *See* Verotoxin
- W**
- WASP, 210  
Wolman disease, 299
- X**
- X-ray crystallography, protein–lipid interactions, 225